{"protocolSection":{"identificationModule":{"nctId":"NCT02542293","orgStudyIdInfo":{"id":"D419AC00003"},"secondaryIdInfos":[{"id":"2015-002197-21","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","officialTitle":"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).","acronym":"NEPTUNE"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-21","type":"ACTUAL"},"completionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-08-26","studyFirstSubmitQcDate":"2015-09-03","studyFirstPostDateStruct":{"date":"2015-09-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-09-20","resultsFirstSubmitQcDate":"2022-04-29","resultsFirstPostDateStruct":{"date":"2022-05-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-12","lastUpdatePostDateStruct":{"date":"2025-09-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.","detailedDescription":"Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients."},"conditionsModule":{"conditions":["Non Small Cell Lung Carcinoma NSCLC"],"keywords":["NSCLC","PDL1","TMB","MEDI4736","Durvalumab","Tremelimumab","OS"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":953,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Combination Therapy","type":"EXPERIMENTAL","description":"Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)","interventionNames":["Biological: Durvalumab +Tremelimumab"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","description":"Standard of Care chemotherapy treatment","interventionNames":["Drug: Paclitaxel + carboplatin","Drug: Gemcitabine + cisplatin","Drug: Gemcitabine + carboplatin","Drug: Pemetrexed + cisplatin","Drug: Pemetrexed + carboplatin"]}],"interventions":[{"type":"BIOLOGICAL","name":"Durvalumab +Tremelimumab","armGroupLabels":["Combination Therapy"]},{"type":"DRUG","name":"Paclitaxel + carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + cisplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + cisplatin","description":"Chemotherapy Agent","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + carboplatin","description":"Chemotherapy Agent","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months)."},{"measure":"OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months)."}],"secondaryOutcomes":[{"measure":"OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive.\n\nbTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \\<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \\<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nbTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available.\n\ntTMB analysis sets are defined same as the bTMB analysis sets.","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months)."},{"measure":"OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive.\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort."},{"measure":"Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \\[RECIST 1.1\\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\ntTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months)."},{"measure":"PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: FAS included all randomized participants prior to end of global recruitment.\n\nChina Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort."},{"measure":"Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD.\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\ntTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months)."},{"measure":"ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD.\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort."},{"measure":"Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months)."},{"measure":"DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort."},{"measure":"Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months."},{"measure":"APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months."},{"measure":"Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months)."},{"measure":"PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort."},{"measure":"OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","timeFrame":"Months 12, 18 and 24"},{"measure":"OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","timeFrame":"Months 12, 18 and 24"},{"measure":"Serum Concentrations of Durvalumab","description":"Blood samples were collected to determine the serum concentration of durvalumab.","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3"},{"measure":"Serum Concentrations of Tremelimumab","description":"Blood samples were collected to determine the serum concentration of tremelimumab.","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3"},{"measure":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \\>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","timeFrame":"At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment."},{"measure":"Number of Participants With ADA Response to Tremelimumab","description":"Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \\>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","timeFrame":"At Weeks 0 and 12; 3 and 6 months after last dose of study treatment."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor inclusion in the study, patients should fulfill the following criteria:\n\n* Aged at least 18 years\n* Documented evidence of Stage IV NSCLC\n* No activating EGFR mutation or ALK rearrangement\n* No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC\n* World Health Organization (WHO) Performance Status of 0 or 1\n* No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines\n\nExclusion Criteria:\n\nPatients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n* Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant\n* Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment.\n* Active or prior documented autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gilberto de Castro","affiliation":"Faculdade de Medicina da Universidade de São Paulo","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Research Site","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"Research Site","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Research Site","city":"Florham Park","state":"New Jersey","zip":"07932","country":"United States","geoPoint":{"lat":40.78788,"lon":-74.38821}},{"facility":"Research Site","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Research Site","city":"East Setauket","state":"New York","zip":"11733","country":"United States","geoPoint":{"lat":40.94149,"lon":-73.10594}},{"facility":"Research Site","city":"Fresh Meadows","state":"New York","zip":"11366","country":"United States","geoPoint":{"lat":40.73482,"lon":-73.79347}},{"facility":"Research Site","city":"Poughkeepsie","state":"New York","zip":"12601","country":"United States","geoPoint":{"lat":41.70037,"lon":-73.92097}},{"facility":"Research Site","city":"Stony Brook","state":"New York","zip":"11794","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"Research Site","city":"Canton","state":"Ohio","zip":"44710","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Research Site","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Research Site","city":"Zanesville","state":"Ohio","zip":"43701","country":"United States","geoPoint":{"lat":39.94035,"lon":-82.01319}},{"facility":"Research Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77090","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Berazategui","zip":"B1884BBF","country":"Argentina","geoPoint":{"lat":-34.76531,"lon":-58.21278}},{"facility":"Research Site","city":"Buenos Aires","zip":"C1025ABI","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Research Site","city":"CABA","zip":"C1426ANZ","country":"Argentina"},{"facility":"Research Site","city":"Córdoba","zip":"5000","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Research Site","city":"La Rioja","zip":"5300","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Research Site","city":"Rosario","zip":"S2000KZE","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Research Site","city":"San Salvador de Jujuy","zip":"4600","country":"Argentina","geoPoint":{"lat":-24.1928,"lon":-65.29342}},{"facility":"Research Site","city":"Santa Rosa","zip":"6300","country":"Argentina","geoPoint":{"lat":-36.61617,"lon":-64.28991}},{"facility":"Research Site","city":"Barretos","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Research Site","city":"Belo Horizonte","zip":"30110-022","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Research Site","city":"Belo Horizonte","zip":"30380-472","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Research Site","city":"Fortaleza","zip":"60336-045","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Research Site","city":"Ijuí","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Research Site","city":"Itajaí","zip":"88301-220","country":"Brazil","geoPoint":{"lat":-26.90778,"lon":-48.66194}},{"facility":"Research Site","city":"Porto Alegre","zip":"90035-003","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Porto Alegre","zip":"90160-093","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Porto Alegre","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"São José do Rio Preto","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Research Site","city":"São Paulo","zip":"01221-020","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"São Paulo","zip":"01323 900","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"São Paulo","zip":"03102-002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"Plovdiv","zip":"4004","country":"Bulgaria","geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Research Site","city":"Shumen","zip":"9700","country":"Bulgaria","geoPoint":{"lat":43.27064,"lon":26.92286}},{"facility":"Research Site","city":"Sofia","zip":"1303","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Sofia","zip":"1330","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Sofia","zip":"1431","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Sofia","zip":"1784","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Varna","zip":"9010","country":"Bulgaria","geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"Research Site","city":"Vratsa","zip":"3000","country":"Bulgaria","geoPoint":{"lat":43.21052,"lon":23.56312}},{"facility":"Research Site","city":"Santiago","zip":"7500713","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Santiago","zip":"7500921","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Santiago","zip":"7520349","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Santiago","zip":"8380456","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Santiago","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Temuco","zip":"4810297","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Research Site","city":"Viña del Mar","zip":"2520612","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Research Site","city":"Beijing","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Changchun","zip":"130000","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Research Site","city":"Chongqing","zip":"400030","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Research Site","city":"Guangzhou","zip":"510100","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Hangzhou","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Ürümqi","zip":"830000","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Research Site","city":"Wuhan","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Wuhan","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Odense C","zip":"5000","country":"Denmark","geoPoint":{"lat":55.40841,"lon":10.39538}},{"facility":"Research Site","city":"Oulu","zip":"FI-90029","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Research Site","city":"Tampere","zip":"FI-33521","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Research Site","city":"Athens","zip":"115 22","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Athens","zip":"14564","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Research Site","city":"Heraklion","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"Research Site","city":"Holargos, Athens","zip":"155 62","country":"Greece"},{"facility":"Research Site","city":"Ioannina","zip":"45000","country":"Greece","geoPoint":{"lat":39.66341,"lon":20.85187}},{"facility":"Research Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Research Site","city":"King's Park","zip":"150001","country":"Hong Kong"},{"facility":"Research Site","city":"Shatin","zip":"00000","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Research Site","city":"Ahmedabad","zip":"380016","country":"India","geoPoint":{"lat":23.02579,"lon":72.58727}},{"facility":"Research Site","city":"Bangalore","zip":"560068","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Research Site","city":"Bangalore","zip":"560076","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Research Site","city":"Chennai","zip":"600035","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Research Site","city":"Gūrgaon","zip":"122001","country":"India","geoPoint":{"lat":28.43549,"lon":79.13486}},{"facility":"Research Site","city":"Karamsad","zip":"388325","country":"India","geoPoint":{"lat":22.54243,"lon":72.90392}},{"facility":"Research Site","city":"New Delhi","zip":"110 085","country":"India","geoPoint":{"lat":28.62137,"lon":77.2148}},{"facility":"Research Site","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Research Site","city":"Jerusalem","zip":"91031","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Research Site","city":"Kfar Saba","zip":"95847","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Research Site","city":"Nahariya","zip":"22100","country":"Israel","geoPoint":{"lat":33.00892,"lon":35.09814}},{"facility":"Research Site","city":"Petah Tikva","zip":"49100","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Research Site","city":"Ramat Gan","zip":"5265601","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Research Site","city":"Bunkyō City","zip":"160-0023","country":"Japan","geoPoint":{"lat":35.5331,"lon":139.4217}},{"facility":"Research Site","city":"Fukushima","zip":"960-1295","country":"Japan","geoPoint":{"lat":37.75,"lon":140.46667}},{"facility":"Research Site","city":"Habikino-shi","zip":"583-8588","country":"Japan"},{"facility":"Research Site","city":"Hirosaki-shi","zip":"036-8545","country":"Japan"},{"facility":"Research Site","city":"Iizuka-shi","zip":"820-8505","country":"Japan"},{"facility":"Research Site","city":"Iwakuni-shi","zip":"740-8510","country":"Japan"},{"facility":"Research Site","city":"Kanazawa","zip":"920-8641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Research Site","city":"Kishiwada-shi","zip":"596-8501","country":"Japan"},{"facility":"Research Site","city":"Kobe","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Research Site","city":"Kurume-shi","zip":"830-0011","country":"Japan"},{"facility":"Research Site","city":"Kyoto","zip":"607-8062","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Research Site","city":"Mitaka-shi","zip":"181-8611","country":"Japan"},{"facility":"Research Site","city":"Nagaoka-shi","zip":"940-2085","country":"Japan"},{"facility":"Research Site","city":"Nagoya","zip":"460-0001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Nagoya","zip":"466-8560","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Niigata","zip":"951-8566","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Research Site","city":"Okayama","zip":"700-8607","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Research Site","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Research Site","city":"Saga","zip":"840-8571","country":"Japan","geoPoint":{"lat":33.23333,"lon":130.3}},{"facility":"Research Site","city":"Sagamihara-shi","zip":"252-0375","country":"Japan"},{"facility":"Research Site","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Research Site","city":"Sendai","zip":"980-0873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Research Site","city":"Tokushima","zip":"770-8503","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"Research Site","city":"Ube-shi","zip":"755-0241","country":"Japan"},{"facility":"Research Site","city":"Wakayama","zip":"641-8510","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}},{"facility":"Research Site","city":"Yokohama","zip":"236-0004","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Yokohama","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Research Site","city":"Kuantan","zip":"25100","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"facility":"Research Site","city":"Kuching","zip":"93586","country":"Malaysia","geoPoint":{"lat":1.55,"lon":110.33333}},{"facility":"Research Site","city":"Acapulco","zip":"39670","country":"Mexico","geoPoint":{"lat":16.11417,"lon":-91.51028}},{"facility":"Research Site","city":"Aguascalientes","zip":"20020","country":"Mexico","geoPoint":{"lat":21.88262,"lon":-102.2843}},{"facility":"Research Site","city":"Mérida","zip":"97134","country":"Mexico","geoPoint":{"lat":20.967,"lon":-89.62318}},{"facility":"Research Site","city":"México","zip":"06100","country":"Mexico","geoPoint":{"lat":31.00435,"lon":-108.15213}},{"facility":"Research Site","city":"México","zip":"14080","country":"Mexico","geoPoint":{"lat":31.00435,"lon":-108.15213}},{"facility":"Research Site","city":"Monterrey","zip":"64710","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Research Site","city":"Arequipa","zip":"AREQUIPA01","country":"Peru","geoPoint":{"lat":-16.39899,"lon":-71.53747}},{"facility":"Research Site","city":"Bellavista","zip":"CALLAO 2","country":"Peru","geoPoint":{"lat":-7.05614,"lon":-76.5911}},{"facility":"Research Site","city":"Lima","zip":"15033","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"L27","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"LIMA 34","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"LIMA 41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Baguio City","zip":"2600","country":"Philippines","geoPoint":{"lat":16.41639,"lon":120.59306}},{"facility":"Research Site","city":"Cebu","zip":"6000","country":"Philippines","geoPoint":{"lat":16.75187,"lon":121.5961}},{"facility":"Research Site","city":"Las Piñas","zip":"PH-1704","country":"Philippines","geoPoint":{"lat":14.45056,"lon":120.98278}},{"facility":"Research Site","city":"Manila","zip":"1000","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"Research Site","city":"Manila","zip":"1003","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"Research Site","city":"Quezon City","zip":"1112","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Research Site","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Research Site","city":"Kielce","zip":"25-734","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Research Site","city":"Krakow","zip":"31-202","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Research Site","city":"Lodz","zip":"93-513","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Research Site","city":"Mrozy","zip":"05-320","country":"Poland","geoPoint":{"lat":52.16609,"lon":21.80263}},{"facility":"Research Site","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Research Site","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Research Site","city":"Warsaw","zip":"01-138","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Wodzisław Śląski","zip":"44-300","country":"Poland","geoPoint":{"lat":50.00377,"lon":18.47205}},{"facility":"Research Site","city":"Amadora","zip":"2720-276","country":"Portugal","geoPoint":{"lat":38.75382,"lon":-9.23083}},{"facility":"Research Site","city":"Lisbon","zip":"1500-650","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Research Site","city":"Porto","zip":"4099-001","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Porto","zip":"4100-180","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Porto","zip":"4200-319","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Doha","zip":"P.O. Box 3050","country":"Qatar","geoPoint":{"lat":25.28545,"lon":51.53096}},{"facility":"Research Site","city":"Suceava","zip":"720237","country":"Romania","geoPoint":{"lat":47.63333,"lon":26.25}},{"facility":"Research Site","city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"115280","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"125367","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Research Site","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197183","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197342","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Dammam","zip":"31444","country":"Saudi Arabia","geoPoint":{"lat":26.43442,"lon":50.10326}},{"facility":"Research Site","city":"Riyadh","zip":"11426","country":"Saudi Arabia","geoPoint":{"lat":24.68773,"lon":46.72185}},{"facility":"Research Site","city":"Riyadh","zip":"12372","country":"Saudi Arabia","geoPoint":{"lat":24.68773,"lon":46.72185}},{"facility":"Research Site","city":"Singapore","zip":"119228","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Singapore","zip":"217562","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Singapore","zip":"258499","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Daegu","zip":"41404","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Research Site","city":"Hwasun-gun","zip":"58128","country":"South Korea"},{"facility":"Research Site","city":"Seoul","zip":"05030","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"06273","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Eskilstuna","zip":"63188","country":"Sweden","geoPoint":{"lat":59.36661,"lon":16.5077}},{"facility":"Research Site","city":"Linköping","zip":"581 85","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"facility":"Research Site","city":"Stockholm","zip":"171 64","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Research Site","city":"Uppsala","zip":"751 85","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"Research Site","city":"Adana","zip":"01120","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Research Site","city":"Ankara","zip":"06200","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Ankara","zip":"06230","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Ankara","zip":"06280","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Ankara","zip":"6500","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Istanbul","zip":"31755","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Istanbul","zip":"34030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Istanbul","zip":"34349","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Research Site","city":"Chernivtsі","zip":"58013","country":"Ukraine"},{"facility":"Research Site","city":"Dnipro","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Research Site","city":"Ivano-Frankivsk","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"Research Site","city":"Kapitanivka Village","zip":"08111","country":"Ukraine"},{"facility":"Research Site","city":"Kharkiv Region","zip":"61070","country":"Ukraine"},{"facility":"Research Site","city":"Kirovohrad","zip":"25006","country":"Ukraine","geoPoint":{"lat":48.50834,"lon":32.26618}},{"facility":"Research Site","city":"Kyiv","zip":"03115","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Research Site","city":"Kyiv","zip":"04107","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Research Site","city":"Liutizh","zip":"07352","country":"Ukraine","geoPoint":{"lat":50.6835,"lon":30.39324}},{"facility":"Research Site","city":"Lviv","zip":"79031","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Research Site","city":"Odesa","zip":"65055","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Research Site","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Research Site","city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Research Site","city":"Vinnytsia","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Research Site","city":"Guildford","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}},{"facility":"Research Site","city":"London","zip":"EC1M 6BQ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"London","zip":"NW1 2PG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"London","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Research Site","city":"Metropolitan Borough of Wirral","zip":"CH63 4JY","country":"United Kingdom","geoPoint":{"lat":53.37616,"lon":-3.10501}},{"facility":"Research Site","city":"Nottingham","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"facility":"Research Site","city":"Taunton","zip":"TA1 5DA","country":"United Kingdom","geoPoint":{"lat":51.01494,"lon":-3.10293}},{"facility":"Research Site","city":"Wolverhampton","zip":"WV10 0QP","country":"United Kingdom","geoPoint":{"lat":52.58547,"lon":-2.12296}}]},"referencesModule":{"references":[{"pmid":"36806898","type":"DERIVED","citation":"Cheng Y, Zhou Q, Han B, Fan Y, Shan L, Chang J, Sun S, Fang J, Chen Y, Sun J, Wu G, Mann H, Naicker K, Shire N, Mok T, de Castro G Jr. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer. 2023 Apr;178:87-95. doi: 10.1016/j.lungcan.2023.01.013. Epub 2023 Feb 1."}],"seeAlsoLinks":[{"label":"Related Info","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00003&amp;attachmentIdentifier=8b9563bd-cf14-4923-8681-fa20813a5b58&amp;fileName=D419AC00003_(Neptune)_Clinical_Study_Protocol_V9.0_Redacted.pdf&amp;versionIdentifier="},{"label":"Related Info","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00003&amp;attachmentIdentifier=9e32a3a4-86d6-47b0-b0f2-852ff8a9c707&amp;fileName=D419AC00003_(Neptune)_Statistical_Analysis_Plan_Redacted.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"823 participants in Global cohort and 160 participants in China cohort were randomized in 1:1 ratio to receive durvalumab + tremelimumab or SoC chemotherapy. China cohort comprised participants from mainland China (30 from Global cohort and 130 randomized after end of Global cohort recruitment). Thus, 953 unique participants were randomized in the study overall. Participants included in both cohorts for Started, Completed and Reasons for Not Completed are not double-counted for participant flow.","recruitmentDetails":"A total of 192 centers across 29 countries in North America, Latin America, Asia, Europe and Gulf countries randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small-cell lung cancer (NSCLC) in this study. First participant was enrolled on 03 November 2015 and final data cut-off (DCO) date was 24 June 2019 for Global cohort and 21 September 2020 for China cohort. SoC = standard of care","groups":[{"id":"FG000","title":"All Participants: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 milligram per kilogram (mg/kg) and tremelimumab 1 mg/kg intravenous (IV) infusion every 4 weeks (Q4W) in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective disease progression (PD), initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"FG001","title":"All Participants: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/square meter (m\\^2) and carboplatin area under the plasma concentration curve (AUC) 5 or 6 mg\\*minute per milliliter (mg\\*min/mL).\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Randomized in overall study","achievements":[{"groupId":"FG000","numSubjects":"474"},{"groupId":"FG001","numSubjects":"479"}]},{"type":"Randomized in Global Cohort","achievements":[{"groupId":"FG000","numSubjects":"410"},{"groupId":"FG001","numSubjects":"413"}]},{"type":"Received Treatment in Global Cohort","achievements":[{"groupId":"FG000","numSubjects":"410"},{"groupId":"FG001","numSubjects":"399"}]},{"type":"Randomized in China Cohort","achievements":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"82"}]},{"type":"Received Treatment in China Cohort","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"78"}]},{"type":"Included in Both Cohorts (Global and China)","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Ongoing in Study at DCO for Final Analysis in Global Cohort","achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"Ongoing in Study at DCO for Final Analysis in China Cohort","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"COMPLETED","comment":"Ongoing in overall study at DCO for final analysis.","achievements":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"83"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"375"},{"groupId":"FG001","numSubjects":"396"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"367"},{"groupId":"FG001","numSubjects":"377"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"19"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Global Cohort: The full analysis set (FAS) included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nParticipants included in both cohorts are not double-counted for the baseline characteristics analysis represented by 'All participants'.","groups":[{"id":"BG000","title":"All Participants: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"BG001","title":"All Participants: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"953"}]}],"measures":[{"title":"Age, Customized","populationDescription":"Baseline data is presented for all participants, as well as separately for the Global and China cohorts.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"All participants","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"953"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"278"},{"groupId":"BG001","value":"244"},{"groupId":"BG002","value":"522"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"431"}]}]},{"title":"Global cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"410"},{"groupId":"BG001","value":"413"},{"groupId":"BG002","value":"823"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"233"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"436"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"387"}]}]},{"title":"China cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"104"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"56"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"Baseline data is presented for all participants, as well as separately for the Global and China cohorts.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"All participants","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"953"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"256"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"347"},{"groupId":"BG001","value":"350"},{"groupId":"BG002","value":"697"}]}]},{"title":"Global cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"410"},{"groupId":"BG001","value":"413"},{"groupId":"BG002","value":"823"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"221"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"305"},{"groupId":"BG002","value":"602"}]}]},{"title":"China cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"43"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"117"}]}]}]},{"title":"Race/Ethnicity, Customized","populationDescription":"Baseline data is presented for all participants, as well as separately for the Global and China cohorts.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"All participants","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"953"}]}],"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"307"},{"groupId":"BG001","value":"289"},{"groupId":"BG002","value":"596"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"315"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"22"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Global cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"410"},{"groupId":"BG001","value":"413"},{"groupId":"BG002","value":"823"}]}],"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"307"},{"groupId":"BG001","value":"289"},{"groupId":"BG002","value":"596"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"185"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"22"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"China cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]}],"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","populationDescription":"Baseline data is presented for all participants, as well as separately for the Global and China cohorts.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"All participants","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"953"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"98"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"423"},{"groupId":"BG001","value":"429"},{"groupId":"BG002","value":"852"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Global cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"410"},{"groupId":"BG001","value":"413"},{"groupId":"BG002","value":"823"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"98"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"359"},{"groupId":"BG001","value":"363"},{"groupId":"BG002","value":"722"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"China cohort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"160"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The bTMB ≥20 mut/Mb analysis set included the subset of participants in the FAS whose blood TMB status was ≥20 mut/Mb at baseline as defined by the GuardantOMNI CDx assay. Only participants randomized in Global cohort were analyzed as bTMB and tissue tumor mutational burden (tTMB) testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"8.6","upperLimit":"15.2"},{"groupId":"OG001","value":"9.1","lowerLimit":"7.8","upperLimit":"12.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Global: Durvalumab + Tremelimumab versus (Vs) Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","pValue":"0.0808","pValueComment":"The 2-sided p-value was calculated using an unstratified log-rank test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.485","ciUpperLimit":"1.045","estimateComment":"The HR and confidence interval (CI) were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."}]},{"type":"PRIMARY","title":"OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The China PD-L1-negative population analysis set included the subset of participants in the China FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue). Only participants randomized in China cohort were analyzed.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).","groups":[{"id":"OG000","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"10.5","upperLimit":"27.4"},{"groupId":"OG001","value":"11.7","lowerLimit":"8.6","upperLimit":"20.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"China: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.322","ciUpperLimit":"1.109","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive.\n\nbTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \\<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \\<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nbTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available.\n\ntTMB analysis sets are defined same as the bTMB analysis sets.","populationDescription":"Participants included in bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb, PD-L1-Negative NSCLC, bTMB \\<20 mut/Mb, bTMB non-evaluable population, tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb, and tTMB ≥8 mut/Mb analysis sets are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"}]}],"classes":[{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"8.6","upperLimit":"15.0"},{"groupId":"OG001","value":"11.9","lowerLimit":"8.5","upperLimit":"15.9"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.6","upperLimit":"12.6"},{"groupId":"OG001","value":"10.3","lowerLimit":"8.3","upperLimit":"12.9"}]}]},{"title":"PD-L1 negative analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"8.1","upperLimit":"14.7"},{"groupId":"OG001","value":"12.5","lowerLimit":"9.9","upperLimit":"16.2"}]}]},{"title":"bTMB <20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"7.7","upperLimit":"12.8"},{"groupId":"OG001","value":"11.5","lowerLimit":"8.8","upperLimit":"13.7"}]}]},{"title":"bTMB non-evaluable analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"7.2","upperLimit":"15.5"},{"groupId":"OG001","value":"10.4","lowerLimit":"9.4","upperLimit":"13.8"}]}]},{"title":"tTMB ≥14 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"9.8","upperLimit":"NA","comment":"Upper limit was not reached."},{"groupId":"OG001","value":"10.6","lowerLimit":"7.0","upperLimit":"20.9"}]}]},{"title":"tTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"7.0","upperLimit":"17.5"},{"groupId":"OG001","value":"13.9","lowerLimit":"9.0","upperLimit":"17.9"}]}]},{"title":"tTMB ≥10 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"7.2","upperLimit":"15.7"},{"groupId":"OG001","value":"10.6","lowerLimit":"9.0","upperLimit":"15.7"}]}]},{"title":"tTMB ≥8 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"7.8","upperLimit":"15.7"},{"groupId":"OG001","value":"10.2","lowerLimit":"8.0","upperLimit":"13.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥16 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.629","ciUpperLimit":"1.201","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.726","ciUpperLimit":"1.213","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 negative analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.786","ciUpperLimit":"1.464","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\<20 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.835","ciUpperLimit":"1.302","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB non-evaluable analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.758","ciUpperLimit":"1.353","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥14 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.309","ciUpperLimit":"1.008","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.560","ciUpperLimit":"1.350","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥10 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.614","ciUpperLimit":"1.251","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥8 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.564","ciUpperLimit":"1.080","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive.\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","populationDescription":"Participants included in FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% analysis sets are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"9.3","upperLimit":"12.6"},{"groupId":"OG001","value":"12.1","lowerLimit":"10.3","upperLimit":"13.5"},{"groupId":"OG002","value":"20.0","lowerLimit":"15.0","upperLimit":"28.7"},{"groupId":"OG003","value":"14.1","lowerLimit":"9.5","upperLimit":"19.4"}]}]},{"title":"PD-L1 TC ≥25% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"9.7","upperLimit":"15.2"},{"groupId":"OG001","value":"10.4","lowerLimit":"8.6","upperLimit":"12.2"},{"groupId":"OG002","value":"36.6","lowerLimit":"15.5","upperLimit":"NA","comment":"Upper limit was not reached."},{"groupId":"OG003","value":"15.8","lowerLimit":"9.0","upperLimit":"26.9"}]}]},{"title":"PD-L1 TC ≥50% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","lowerLimit":"10.0","upperLimit":"19.3"},{"groupId":"OG001","value":"10.5","lowerLimit":"8.7","upperLimit":"12.6"},{"groupId":"OG002","value":"36.6","lowerLimit":"16.9","upperLimit":"NA","comment":"Upper limit was not reached."},{"groupId":"OG003","value":"15.8","lowerLimit":"9.0","upperLimit":"26.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"FAS:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.871","ciUpperLimit":"1.186","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥25% Vs \\<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"FAS:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.480","ciUpperLimit":"1.018","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>= 25% Vs \\< 25 and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥25% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.654","ciUpperLimit":"1.078","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥ 25% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.289","ciUpperLimit":"1.065","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.587","ciUpperLimit":"1.081","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer OS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.222","ciUpperLimit":"0.955","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \\[RECIST 1.1\\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\ntTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb, tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb, and tTMB ≥8 mut/Mb analysis sets are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"}]}],"classes":[{"title":"bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"2.7","upperLimit":"5.6"},{"groupId":"OG001","value":"5.1","lowerLimit":"4.2","upperLimit":"5.6"}]}]},{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"2.8","upperLimit":"5.5"},{"groupId":"OG001","value":"5.5","lowerLimit":"4.4","upperLimit":"5.8"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"2.8","upperLimit":"4.8"},{"groupId":"OG001","value":"5.1","lowerLimit":"4.4","upperLimit":"5.6"}]}]},{"title":"tTMB ≥14 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"5.2","upperLimit":"22.3"},{"groupId":"OG001","value":"5.8","lowerLimit":"4.4","upperLimit":"7.9"}]}]},{"title":"tTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"3.8","upperLimit":"6.9"},{"groupId":"OG001","value":"5.8","lowerLimit":"4.2","upperLimit":"6.6"}]}]},{"title":"tTMB ≥10 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"2.8","upperLimit":"5.5"},{"groupId":"OG001","value":"5.1","lowerLimit":"4.2","upperLimit":"5.8"}]}]},{"title":"tTMB ≥8 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.9","upperLimit":"5.5"},{"groupId":"OG001","value":"5.0","lowerLimit":"4.2","upperLimit":"5.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥20 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.514","ciUpperLimit":"1.146","estimateComment":"The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥16 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.623","ciUpperLimit":"1.189","estimateComment":"The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.714","ciUpperLimit":"1.193","estimateComment":"The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥14 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.258","ciUpperLimit":"0.818","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.524","ciUpperLimit":"1.228","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥10 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.585","ciUpperLimit":"1.177","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥8 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.534","ciUpperLimit":"1.017","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: FAS included all randomized participants prior to end of global recruitment.\n\nChina Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","populationDescription":"Participants included in PD-L1-negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% analysis sets are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"2.8","upperLimit":"5.2"},{"groupId":"OG001","value":"5.6","lowerLimit":"4.6","upperLimit":"6.0"},{"groupId":"OG002","value":"5.1","lowerLimit":"2.8","upperLimit":"7.2"},{"groupId":"OG003","value":"6.0","lowerLimit":"4.0","upperLimit":"7.5"}]}]},{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"2.9","upperLimit":"4.2"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.3","upperLimit":"5.7"},{"groupId":"OG002","value":"4.2","lowerLimit":"2.8","upperLimit":"7.2"},{"groupId":"OG003","value":"6.0","lowerLimit":"5.5","upperLimit":"7.5"}]}]},{"title":"PD-L1 TC ≥25% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"3.2","upperLimit":"5.7"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"5.6"},{"groupId":"OG002","value":"6.8","lowerLimit":"4.1","upperLimit":"8.4"},{"groupId":"OG003","value":"5.7","lowerLimit":"4.2","upperLimit":"8.5"}]}]},{"title":"PD-L1 TC ≥50% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.1","upperLimit":"6.0"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.3","upperLimit":"5.6"},{"groupId":"OG002","value":"6.8","lowerLimit":"4.2","upperLimit":"20.2"},{"groupId":"OG003","value":"5.7","lowerLimit":"4.2","upperLimit":"8.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1-negative analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.810","ciUpperLimit":"1.517","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1-negative analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.592","ciUpperLimit":"2.141","estimateComment":"The HR and CI interval were calculated using an stratified Cox proportional hazards model, adjusting histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"FAS:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.924","ciUpperLimit":"1.253","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥25% Vs \\<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"FAS:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.655","ciUpperLimit":"1.362","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥ 25% Vs \\< 25%) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥25% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.621","ciUpperLimit":"1.024","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥ 25% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.389","ciUpperLimit":"1.317","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.542","ciUpperLimit":"1.010","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer PFS than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.335","ciUpperLimit":"1.251","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets","description":"The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD.\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.\n\ntTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb, tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb, and tTMB ≥8 mut/Mb analysis sets with measurable disease are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"}]}],"classes":[{"title":"bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.5"},{"groupId":"OG001","value":"43.3"}]}]},{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.2"},{"groupId":"OG001","value":"46.1"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.7"},{"groupId":"OG001","value":"42.0"}]}]},{"title":"tTMB ≥14 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.3"},{"groupId":"OG001","value":"44.7"}]}]},{"title":"tTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"41.8"}]}]},{"title":"tTMB ≥10 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.7"},{"groupId":"OG001","value":"42.5"}]}]},{"title":"tTMB ≥8 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.7"},{"groupId":"OG001","value":"41.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥20 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.236","ciUpperLimit":"1.030"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥16 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.288","ciUpperLimit":"0.968"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.336","ciUpperLimit":"0.908"},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥14 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.752","ciUpperLimit":"5.234"},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.482","ciUpperLimit":"2.214"},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥10 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.430","ciUpperLimit":"1.548"},{"groupIds":["OG000","OG001"],"groupDescription":"tTMB ≥8 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.456","ciUpperLimit":"1.486"}]},{"type":"SECONDARY","title":"ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets","description":"The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD.\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nPD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.","populationDescription":"Participants included in PD-L1-negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% analysis sets with measurable disease are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.1"},{"groupId":"OG001","value":"38.8"},{"groupId":"OG002","value":"23.1"},{"groupId":"OG003","value":"41.4"}]}]},{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"412"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.9"},{"groupId":"OG001","value":"41.7"},{"groupId":"OG002","value":"35.9"},{"groupId":"OG003","value":"39.0"}]}]},{"title":"PD-L1 TC ≥25% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.2"},{"groupId":"OG001","value":"43.9"},{"groupId":"OG002","value":"54.8"},{"groupId":"OG003","value":"40.6"}]}]},{"title":"PD-L1 TC ≥50% analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.4"},{"groupId":"OG001","value":"44.0"},{"groupId":"OG002","value":"60.0"},{"groupId":"OG003","value":"46.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1-negative analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.245","ciUpperLimit":"0.869","estimateComment":"The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1-negative analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","statisticalMethod":"Binomial exact test","paramType":"Odds Ratio (OR)","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.124","ciUpperLimit":"1.337"},{"groupIds":["OG000","OG001"],"groupDescription":"FAS:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.356","ciUpperLimit":"0.647","estimateComment":"The analysis was performed using logistic regression adjusting for PD-L1 status (≥25% Vs \\<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG002","OG003"],"groupDescription":"FAS:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Odds Ratio (OR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.450","ciUpperLimit":"1.660","estimateComment":"The analysis was performed using logistic regression, adjusting for PD-L1 status (\\>= 25% Vs \\< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥25% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.443","ciUpperLimit":"1.079","estimateComment":"The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥ 25% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Odds Ratio (OR)","paramValue":"1.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.658","ciUpperLimit":"4.919","estimateComment":"The analysis was performed using logistic regression, adjusting for PD-L1 status (\\>= 25% Vs \\< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.449","ciUpperLimit":"1.291","estimateComment":"The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1 TC ≥50% analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nAn odds ratio \\>1 favors Durvalumab + Tremelimumab combination therapy over SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Odds Ratio (OR)","paramValue":"1.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.585","ciUpperLimit":"5.270","estimateComment":"The analysis was performed using logistic regression, adjusting for PD-L1 status (\\>= 25% Vs \\< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."}]},{"type":"SECONDARY","title":"Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, and bTMB ≥12 mut/Mb analysis sets are reported in this outcome measure. Only participants with objective response and randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"172"}]}],"classes":[{"title":"bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"6.7","upperLimit":"21.5"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.0","upperLimit":"6.9"}]}]},{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"4.2","upperLimit":"21.5"},{"groupId":"OG001","value":"4.3","lowerLimit":"3.0","upperLimit":"5.9"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"6.7","upperLimit":"18.8"},{"groupId":"OG001","value":"4.3","lowerLimit":"3.0","upperLimit":"5.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥20 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.113","ciUpperLimit":"0.532","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥16 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.196","ciUpperLimit":"0.639","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.233","ciUpperLimit":"0.611","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","populationDescription":"Participants included in PD-L1-negative NSCLC and FAS analysis sets are reported in this outcome measure. Only participants with objective response were included in this analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"}]}],"classes":[{"title":"PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"2.8","upperLimit":"18.8"},{"groupId":"OG001","value":"4.9","lowerLimit":"4.2","upperLimit":"6.1"},{"groupId":"OG002","value":"10.5","lowerLimit":"1.4","upperLimit":"NA","comment":"Upper limit was not reached."},{"groupId":"OG003","value":"6.1","lowerLimit":"3.0","upperLimit":"11.7"}]}]},{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"6.9","upperLimit":"15.2"},{"groupId":"OG001","value":"4.9","lowerLimit":"4.2","upperLimit":"5.6"},{"groupId":"OG002","value":"12.9","lowerLimit":"5.4","upperLimit":"33.6"},{"groupId":"OG003","value":"6.1","lowerLimit":"4.4","upperLimit":"7.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1-negative analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.199","ciUpperLimit":"0.787","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1-negative analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.79","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.183","ciUpperLimit":"2.860","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"FAS:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.324","ciUpperLimit":"0.588","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"FAS:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab combination therapy to be associated with a longer DoR than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.193","ciUpperLimit":"0.761","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>= 25% Vs \\< 25%) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, and bTMB ≥12 mut/Mb analysis sets are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"classes":[{"title":"bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","lowerLimit":"15.7","upperLimit":"36.6"},{"groupId":"OG001","value":"7.0","lowerLimit":"1.9","upperLimit":"16.8"}]}]},{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","lowerLimit":"14.1","upperLimit":"31.1"},{"groupId":"OG001","value":"12.3","lowerLimit":"6.1","upperLimit":"20.8"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","lowerLimit":"15.2","upperLimit":"28.9"},{"groupId":"OG001","value":"13.8","lowerLimit":"8.3","upperLimit":"20.6"}]}]}]},{"type":"SECONDARY","title":"APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","populationDescription":"Participants included in PD-L1-negative NSCLC and FAS analysis sets are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"10.9","upperLimit":"26.9"},{"groupId":"OG001","value":"12.1","lowerLimit":"6.3","upperLimit":"19.9"},{"groupId":"OG002","value":"15.6","lowerLimit":"4.0","upperLimit":"34.4"},{"groupId":"OG003","value":"11.3","lowerLimit":"2.3","upperLimit":"28.5"}]}]},{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","lowerLimit":"16.4","upperLimit":"24.3"},{"groupId":"OG001","value":"14.9","lowerLimit":"11.4","upperLimit":"18.9"},{"groupId":"OG002","value":"23.9","lowerLimit":"14.8","upperLimit":"34.2"},{"groupId":"OG003","value":"16.6","lowerLimit":"8.5","upperLimit":"27.0"}]}]}]},{"type":"SECONDARY","title":"Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, and bTMB ≥12 mut/Mb analysis sets are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"classes":[{"title":"bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"8.5","upperLimit":"14.4"},{"groupId":"OG001","value":"8.6","lowerLimit":"7.3","upperLimit":"12.6"}]}]},{"title":"bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.5","upperLimit":"14.1"},{"groupId":"OG001","value":"10.5","lowerLimit":"8.0","upperLimit":"13.2"}]}]},{"title":"bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"8.2","upperLimit":"11.7"},{"groupId":"OG001","value":"9.0","lowerLimit":"7.8","upperLimit":"10.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥20 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.494","ciUpperLimit":"1.058","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥16 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.607","ciUpperLimit":"1.151","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB ≥12 mut/Mb analysis set: Global: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.689","ciUpperLimit":"1.146","estimateComment":"The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","populationDescription":"Participants included in PD-L1-negative NSCLC and FAS analysis sets are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"6.9","upperLimit":"12.8"},{"groupId":"OG001","value":"12.4","lowerLimit":"8.8","upperLimit":"14.9"},{"groupId":"OG002","value":"13.8","lowerLimit":"10.1","upperLimit":"27.4"},{"groupId":"OG003","value":"10.3","lowerLimit":"6.5","upperLimit":"14.1"}]}]},{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"8.2","upperLimit":"10.9"},{"groupId":"OG001","value":"10.4","lowerLimit":"9.1","upperLimit":"11.5"},{"groupId":"OG002","value":"15.5","lowerLimit":"12.5","upperLimit":"24.5"},{"groupId":"OG003","value":"12.9","lowerLimit":"9.2","upperLimit":"15.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"PD-L1-negative analysis set:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.748","ciUpperLimit":"1.388","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"PD-L1-negative analysis set:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.360","ciUpperLimit":"1.219","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."},{"groupIds":["OG000","OG001"],"groupDescription":"FAS:\n\nGlobal: Durvalumab + Tremelimumab Vs Global: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.845","ciUpperLimit":"1.147","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>= 25% Vs \\< 25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach."},{"groupIds":["OG002","OG003"],"groupDescription":"FAS:\n\nChina: Durvalumab + Tremelimumab Vs China: SoC Chemotherapy\n\nA HR \\<1 favors Durvalumab + Tremelimumab to be associated with a longer time to second progression than SoC.","nonInferiorityType":"OTHER","nonInferiorityComment":"The study was not designed or powered to show statistical significance for efficacy endpoints in the China cohort, so all statistical analyses for the China cohort were considered exploratory.","paramType":"Hazard Ratio (HR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.492","ciUpperLimit":"1.030","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach."}]},{"type":"SECONDARY","title":"OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).\n\nbTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.","populationDescription":"Participants included in bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb, and bTMB ≥12 mut/Mb analysis sets are reported in this outcome measure. Only participants randomized in Global cohort were analyzed as bTMB and tTMB testing was not performed in China cohort.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Months 12, 18 and 24","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"classes":[{"title":"Month 12: bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","lowerLimit":"37.1","upperLimit":"60.4"},{"groupId":"OG001","value":"40.8","lowerLimit":"28.3","upperLimit":"52.9"}]}]},{"title":"Month 12: bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","lowerLimit":"40.0","upperLimit":"60.2"},{"groupId":"OG001","value":"48.9","lowerLimit":"38.2","upperLimit":"58.8"}]}]},{"title":"Month 12: bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","lowerLimit":"38.5","upperLimit":"54.8"},{"groupId":"OG001","value":"44.6","lowerLimit":"36.1","upperLimit":"52.7"}]}]},{"title":"Month 18: bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","lowerLimit":"25.1","upperLimit":"47.4"},{"groupId":"OG001","value":"20.4","lowerLimit":"11.3","upperLimit":"31.4"}]}]},{"title":"Month 18: bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","lowerLimit":"25.9","upperLimit":"45.1"},{"groupId":"OG001","value":"28.5","lowerLimit":"19.5","upperLimit":"38.1"}]}]},{"title":"Month 18: bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","lowerLimit":"22.1","upperLimit":"36.9"},{"groupId":"OG001","value":"27.8","lowerLimit":"20.6","upperLimit":"35.4"}]}]},{"title":"Month 24: bTMB ≥20 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","lowerLimit":"16.4","upperLimit":"36.8"},{"groupId":"OG001","value":"13.6","lowerLimit":"6.4","upperLimit":"23.6"}]}]},{"title":"Month 24: bTMB ≥16 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"15.8","upperLimit":"33.2"},{"groupId":"OG001","value":"18.2","lowerLimit":"11.0","upperLimit":"26.9"}]}]},{"title":"Month 24: bTMB ≥12 mut/Mb analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","lowerLimit":"15.0","upperLimit":"28.4"},{"groupId":"OG001","value":"19.0","lowerLimit":"12.9","upperLimit":"26.0"}]}]}]},{"type":"SECONDARY","title":"OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).\n\nPD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \\<1% PD-L1-membrane expression in tumoral tissue).\n\nGlobal Cohort: The FAS included all randomized participants prior to the end of global recruitment.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","populationDescription":"Participants included in PD-L1-negative NSCLC and FAS analysis sets are reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Months 12, 18 and 24","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."},{"id":"OG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"classes":[{"title":"Month 12: PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","lowerLimit":"37.2","upperLimit":"57.6"},{"groupId":"OG001","value":"52.8","lowerLimit":"42.6","upperLimit":"61.9"},{"groupId":"OG002","value":"68.0","lowerLimit":"46.1","upperLimit":"82.5"},{"groupId":"OG003","value":"46.4","lowerLimit":"27.6","upperLimit":"63.3"}]}]},{"title":"Month 12: FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","lowerLimit":"42.8","upperLimit":"52.5"},{"groupId":"OG001","value":"50.0","lowerLimit":"45.0","upperLimit":"54.8"},{"groupId":"OG002","value":"72.8","lowerLimit":"61.3","upperLimit":"81.3"},{"groupId":"OG003","value":"53.1","lowerLimit":"41.7","upperLimit":"63.2"}]}]},{"title":"Month 18: PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","lowerLimit":"24.5","upperLimit":"43.9"},{"groupId":"OG001","value":"34.5","lowerLimit":"25.4","upperLimit":"43.8"},{"groupId":"OG002","value":"44.0","lowerLimit":"24.5","upperLimit":"61.9"},{"groupId":"OG003","value":"39.3","lowerLimit":"21.7","upperLimit":"56.5"}]}]},{"title":"Month 18: FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","lowerLimit":"30.2","upperLimit":"39.5"},{"groupId":"OG001","value":"34.6","lowerLimit":"30.0","upperLimit":"39.3"},{"groupId":"OG002","value":"54.6","lowerLimit":"42.8","upperLimit":"64.9"},{"groupId":"OG003","value":"41.8","lowerLimit":"31.0","upperLimit":"52.3"}]}]},{"title":"Month 24: PD-L1-negative NSCLC analysis set","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","lowerLimit":"14.0","upperLimit":"31.3"},{"groupId":"OG001","value":"22.3","lowerLimit":"14.7","upperLimit":"30.9"},{"groupId":"OG002","value":"36.0","lowerLimit":"18.2","upperLimit":"54.2"},{"groupId":"OG003","value":"17.9","lowerLimit":"6.5","upperLimit":"33.7"}]}]},{"title":"Month 24: FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"413"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"21.6","upperLimit":"30.1"},{"groupId":"OG001","value":"23.4","lowerLimit":"19.4","upperLimit":"27.7"},{"groupId":"OG002","value":"44.2","lowerLimit":"32.9","upperLimit":"54.8"},{"groupId":"OG003","value":"30.4","lowerLimit":"20.7","upperLimit":"40.6"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Durvalumab","description":"Blood samples were collected to determine the serum concentration of durvalumab.","populationDescription":"Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram per milliliter (µg/mL)","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"78"}]}],"classes":[{"title":"Week 0: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"401"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 µg/mL."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"NA = Below lower limit of quantification (LLOQ). The LLOQ = 0.05 µg/mL."}]}]},{"title":"Week 0: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"399"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"418.6","spread":"74.8"},{"groupId":"OG001","value":"392.7","spread":"48.9"}]}]},{"title":"Week 12: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":"138.1"},{"groupId":"OG001","value":"72.4","spread":"55.0"}]}]},{"title":"Week 12: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"434.3","spread":"105.6"},{"groupId":"OG001","value":"448.9","spread":"40.0"}]}]},{"title":"Week 24: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108.8","spread":"95.7"},{"groupId":"OG001","value":"85.6","spread":"93.9"}]}]},{"title":"Follow-up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"253.9"},{"groupId":"OG001","value":"5.4","spread":"351.7"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Tremelimumab","description":"Blood samples were collected to determine the serum concentration of tremelimumab.","populationDescription":"Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/mL","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"78"}]}],"classes":[{"title":"Week 0: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"402"},{"groupId":"OG001","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 µg/mL."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 µg/mL."}]}]},{"title":"Week 0: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"398"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":"38.7"},{"groupId":"OG001","value":"18.4","spread":"43.3"}]}]},{"title":"Week 12: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"99.6"},{"groupId":"OG001","value":"3.3","spread":"64.6"}]}]},{"title":"Week 12: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":"67.4"},{"groupId":"OG001","value":"23.2","spread":"43.4"}]}]},{"title":"Follow-up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 µg/mL."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 µg/mL."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \\>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","populationDescription":"Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nThe denominator for calculation of percentage for all categories is the number of ADA evaluable participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"ADA positive at any visit (ADA prevalence)","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"1"}]}]},{"title":"Treatment-emergent ADA positive (ADA incidence)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"1"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Treatment-induced ADA (positive post-baseline only)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"1"}]}]},{"title":"ADA positive post-baseline and positive at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Persistent positive","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"1"}]}]},{"title":"Transient positive","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"nAb positive at any visit","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"ADA positive at baseline and not detected post-baseline","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ADA Response to Tremelimumab","description":"Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \\>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","populationDescription":"Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.\n\nChina Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.\n\nThe denominator for calculation of percentage for all categories is the number of ADA evaluable participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.","groups":[{"id":"OG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."},{"id":"OG001","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"ADA positive at any visit (ADA prevalence)","categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"2"}]}]},{"title":"Treatment-emergent ADA positive (ADA incidence)","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"1"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Treatment-induced ADA (positive post-baseline only)","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"1"}]}]},{"title":"ADA positive post-baseline and positive at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"Persistent positive","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"0"}]}]},{"title":"Transient positive","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"}]}]},{"title":"nAb positive at any visit","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"}]}]},{"title":"ADA positive at baseline and not detected post-baseline","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Assessed until final analysis DCO for each cohort (24 June 2019 for Global Cohort and 21 September 2020 for China Cohort); maximum timeframe of approximately 44 months for each cohort.","description":"Global Cohort: The safety analysis set included all participants recruited prior to end of the global recruitment who received at least 1 dose of study treatment.\n\nChina Cohort: The China safety analysis set included all participants recruited in the China cohort who received at least 1 dose of study treatment.\n\nAll-Cause Mortality: Data from participants included in Global and China FAS was summarized separately. 30 participants in China cohort were also included in Global cohort.","eventGroups":[{"id":"EG000","title":"Global: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.","deathsNumAffected":328,"deathsNumAtRisk":410,"seriousNumAffected":193,"seriousNumAtRisk":410,"otherNumAffected":310,"otherNumAtRisk":410},{"id":"EG001","title":"Global: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted).","deathsNumAffected":329,"deathsNumAtRisk":413,"seriousNumAffected":112,"seriousNumAtRisk":399,"otherNumAffected":349,"otherNumAtRisk":399},{"id":"EG002","title":"China: Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued to receive durvalumab 20 mg/kg Q4W, starting on Week 16 until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.","deathsNumAffected":50,"deathsNumAtRisk":78,"seriousNumAffected":32,"seriousNumAtRisk":77,"otherNumAffected":73,"otherNumAtRisk":77},{"id":"EG003","title":"China: SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until objective PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous participants only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous participants only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous participants only; pemetrexed maintenance dose was permitted).","deathsNumAffected":62,"deathsNumAtRisk":82,"seriousNumAffected":22,"seriousNumAtRisk":78,"otherNumAffected":77,"otherNumAtRisk":78}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":78}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Haematotoxicity","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Optic neuropathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Autoimmune pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Immune-mediated pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Vascular stent occlusion","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Bile duct stenosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hepatitis toxic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Labyrinthitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":27,"numAtRisk":410},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":78}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Snake bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Blood calcium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Blood corticotrophin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":8,"numAffected":2,"numAtRisk":78}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Tumour lysis syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Paraneoplastic arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Polymyositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Tumour invasion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Carotid artery disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Lateral medullary syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Urethral pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":78}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":78}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":410},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Superior vena cava stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":59,"numAtRisk":410},{"groupId":"EG001","numEvents":201,"numAffected":146,"numAtRisk":399},{"groupId":"EG002","numEvents":35,"numAffected":25,"numAtRisk":77},{"groupId":"EG003","numEvents":74,"numAffected":53,"numAtRisk":78}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":55,"numAffected":38,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":21,"numAffected":13,"numAtRisk":78}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":113,"numAffected":71,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":15,"numAffected":10,"numAtRisk":78}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":73,"numAffected":50,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":78}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":34,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":51,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":399},{"groupId":"EG002","numEvents":12,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":78}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":78}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":78}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":59,"numAtRisk":410},{"groupId":"EG001","numEvents":90,"numAffected":84,"numAtRisk":399},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":77},{"groupId":"EG003","numEvents":12,"numAffected":9,"numAtRisk":78}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":72,"numAtRisk":410},{"groupId":"EG001","numEvents":53,"numAffected":40,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":78}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":57,"numAtRisk":410},{"groupId":"EG001","numEvents":244,"numAffected":128,"numAtRisk":399},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":77},{"groupId":"EG003","numEvents":108,"numAffected":33,"numAtRisk":78}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":410},{"groupId":"EG001","numEvents":40,"numAffected":27,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":29,"numAtRisk":410},{"groupId":"EG001","numEvents":80,"numAffected":57,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":34,"numAffected":19,"numAtRisk":78}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":50,"numAtRisk":410},{"groupId":"EG001","numEvents":59,"numAffected":52,"numAtRisk":399},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":77},{"groupId":"EG003","numEvents":16,"numAffected":12,"numAtRisk":78}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":56,"numAtRisk":410},{"groupId":"EG001","numEvents":95,"numAffected":73,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":78}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":13,"numAffected":7,"numAtRisk":78}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":78}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":29,"numAtRisk":410},{"groupId":"EG001","numEvents":23,"numAffected":16,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":78}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":40,"numAtRisk":410},{"groupId":"EG001","numEvents":35,"numAffected":32,"numAtRisk":399},{"groupId":"EG002","numEvents":21,"numAffected":12,"numAtRisk":77},{"groupId":"EG003","numEvents":10,"numAffected":9,"numAtRisk":78}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":78}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":410},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":399},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":33,"numAtRisk":410},{"groupId":"EG001","numEvents":48,"numAffected":34,"numAtRisk":399},{"groupId":"EG002","numEvents":27,"numAffected":22,"numAtRisk":77},{"groupId":"EG003","numEvents":49,"numAffected":22,"numAtRisk":78}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":34,"numAffected":21,"numAtRisk":77},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":78}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":27,"numAtRisk":410},{"groupId":"EG001","numEvents":41,"numAffected":28,"numAtRisk":399},{"groupId":"EG002","numEvents":39,"numAffected":25,"numAtRisk":77},{"groupId":"EG003","numEvents":38,"numAffected":20,"numAtRisk":78}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":78}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":78}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":78}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":8,"numAtRisk":410},{"groupId":"EG001","numEvents":36,"numAffected":28,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":12,"numAffected":9,"numAtRisk":78}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":78}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":8,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":78}]},{"term":"Blood thyroid stimulating hormone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":8,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":33,"numAffected":19,"numAtRisk":77},{"groupId":"EG003","numEvents":15,"numAffected":10,"numAtRisk":78}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":78}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":21,"numAtRisk":410},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":399},{"groupId":"EG002","numEvents":26,"numAffected":15,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":4,"numAtRisk":410},{"groupId":"EG001","numEvents":68,"numAffected":29,"numAtRisk":399},{"groupId":"EG002","numEvents":8,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":94,"numAffected":35,"numAtRisk":78}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":51,"numAffected":30,"numAtRisk":399},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":30,"numAffected":15,"numAtRisk":78}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":45,"numAtRisk":410},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":399},{"groupId":"EG002","numEvents":16,"numAffected":16,"numAtRisk":77},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":78}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":9,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":126,"numAffected":35,"numAtRisk":78}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":79,"numAffected":69,"numAtRisk":410},{"groupId":"EG001","numEvents":88,"numAffected":72,"numAtRisk":399},{"groupId":"EG002","numEvents":14,"numAffected":14,"numAtRisk":77},{"groupId":"EG003","numEvents":37,"numAffected":22,"numAtRisk":78}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":16,"numAffected":11,"numAtRisk":77},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":78}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":78}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":8,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":78}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":31,"numAffected":23,"numAtRisk":77},{"groupId":"EG003","numEvents":17,"numAffected":15,"numAtRisk":78}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":78}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":13,"numAffected":7,"numAtRisk":77},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":78}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":19,"numAffected":13,"numAtRisk":77},{"groupId":"EG003","numEvents":13,"numAffected":8,"numAtRisk":78}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":410},{"groupId":"EG001","numEvents":24,"numAffected":20,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":78}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":38,"numAffected":19,"numAtRisk":77},{"groupId":"EG003","numEvents":20,"numAffected":15,"numAtRisk":78}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":14,"numAffected":7,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":78}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":19,"numAffected":16,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":78}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":410},{"groupId":"EG001","numEvents":53,"numAffected":27,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":410},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":77},{"groupId":"EG003","numEvents":16,"numAffected":7,"numAtRisk":78}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":410},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":399},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":78}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":24,"numAtRisk":410},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":399},{"groupId":"EG002","numEvents":8,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":28,"numAffected":23,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":410},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":399},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":78}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":46,"numAtRisk":410},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":399},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":77},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":78}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":30,"numAtRisk":410},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":399},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":78}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":19,"numAffected":10,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":78}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":410},{"groupId":"EG001","numEvents":50,"numAffected":50,"numAtRisk":399},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":78}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":51,"numAtRisk":410},{"groupId":"EG001","numEvents":25,"numAffected":11,"numAtRisk":399},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":78}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":58,"numAtRisk":410},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":399},{"groupId":"EG002","numEvents":16,"numAffected":12,"numAtRisk":77},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":78}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":78}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":399},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":18,"numAffected":5,"numAtRisk":78}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Analysis of the China cohort was performed to evaluate the consistency of efficacy and safety in Chinese participants with the global cohort in order to meet China health regulatory requirements and was not powered for a formal assessment of statistical significance."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-01-20","uploadDate":"2021-09-20T09:39","filename":"Prot_000.pdf","size":1365246},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-05-17","uploadDate":"2021-09-20T09:39","filename":"SAP_001.pdf","size":653833}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["United Arab Emirates"]},"interventionBrowseModule":{"meshes":[{"id":"C053518","term":"CP protocol"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}